{"schema_version":"secwatch.filing_event.v1","accession":"0001576280-22-000118","form_type":"8-K","ticker":"GH","cik":"0001576280","company_name":"Guardant Health, Inc.","filed_at":"2022-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.240222+00:00","generated_at":"2026-06-21T04:08:22.679046+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Guardant Health ECLIPSE blood test shows 83% sensitivity for colorectal cancer in 20,000+ patient study","bullets":["ECLIPSE study: 83% sensitivity for CRC detection, 90% specificity vs. negative colonoscopy.","Advanced adenoma sensitivity at 13%; cfDNA-only test outperformed cfDNA+protein version.","Plans PMA submission to FDA in Q1 2023; results exceed CMS reimbursement criteria.","Blood test completion rate 90% vs. 43-66% for stool tests; aims to address 49M unscreened adults.","Guardant expands test to other cancers including lung cancer; co-CEO cites breakthrough in blood-based screening."],"urls":{"canonical":"https://secwatch.observer/filing/0001576280-22-000118","json":"https://secwatch.observer/filing/0001576280-22-000118.json","markdown":"https://secwatch.observer/filing/0001576280-22-000118.md","text":"https://secwatch.observer/filing/0001576280-22-000118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576280/000157628022000118/0001576280-22-000118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576280/000157628022000118/gh-20221215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T04:08:22.679046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}